Therini Bio Announces Interim Results from the Phase 1

- THN391 was found to be safe and well-tolerated -- THN391 demonstrated a prolonged half-life and dose proportional Cmax levels -- The data will be...

Related Keywords

Sacramento ,California ,United States ,Boston ,Massachusetts ,University Of California San Francisco ,University Of California San Diego ,Jeffrey Stavenhagen ,Therini Bio ,Eli Lilly ,Katerina Akassoglou ,Leslie Schulze ,Alzheimer Drug Discovery Foundation ,Boston Park Plaza Hotel ,Sv Health Investor Impact Medicine Fund ,Dementia Discovery Fund ,Therini Bio Inc ,Clinical Development ,Ventures Fund ,Clinical Trials ,Chief Scientific Officer ,Beyond Amyloid ,Translation Studies ,Novel Anti Fibrin Antibody ,Poster Hall ,Gladstone Institutes ,California San Francisco ,California San Diego ,Drug Discovery Foundation ,Dolby Family Ventures ,Better World ,Sanofi Ventures ,Investor Impact Medicine ,Nc ,